At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BK4139 Biotechnology
Trading 02-18 12:56:23 EST
74.71
-0.15
-0.20%
High74.94Low74.39Vol418.62M
Open74.86D1 Closing74.86Amplitude0.72%
Mkt Cap0.00Tradable Cap0.00Total Shares0.00
T/O6.12BT/O Rate--Tradable Shares0.00
P/B7.4028ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and RenovoRx (RNXT)
TIPRANKS  ·  02-18 16:10
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and RenovoRx (RNXT)
U.S. RESEARCH ROUNDUP-Goosehead Insurance, Trade Desk, Watsco
Reuters  ·  02-18 15:21
U.S. RESEARCH ROUNDUP-Goosehead Insurance, Trade Desk, Watsco
Analyst Warns Bezuclastinib’s FDA Breakthrough and RTOR Status May Not Translate Into Faster Approvals or Investor Gains
TIPRANKS  ·  02-18 14:00
Analyst Warns Bezuclastinib’s FDA Breakthrough and RTOR Status May Not Translate Into Faster Approvals or Investor Gains
A Look At Savara (SVRA) Valuation After Recent FDA Progress And Strengthened Outlook
Simply Wall St.  ·  02-18 13:28
A Look At Savara (SVRA) Valuation After Recent FDA Progress And Strengthened Outlook
Clinical Hold Lift On MAGNITUDE-2 Resets Risk Reward For Intellia Investors
Simply Wall St.  ·  02-18 13:25
Clinical Hold Lift On MAGNITUDE-2 Resets Risk Reward For Intellia Investors
HCW Biologics Prices $1.5 Million Offering With Warrants at $0.6055 Per Share
Reuters  ·  02-18 10:51
HCW Biologics Prices $1.5 Million Offering With Warrants at $0.6055 Per Share
HCW Biologics Announces Pricing of $1.5 Million Follow-on Offering Priced at-the-Market Under Nasdaq Rules
THOMSON REUTERS  ·  02-18 10:50
HCW Biologics Announces Pricing of $1.5 Million Follow-on Offering Priced at-the-Market Under Nasdaq Rules
Press Release: HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
Dow Jones  ·  02-18 10:50
Press Release: HCW Biologics Announces Pricing of $1.5 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
ADMA Biologics CEO Adam S. Grossman Reports Disposal of Common Shares
Reuters  ·  02-18 10:40
ADMA Biologics CEO Adam S. Grossman Reports Disposal of Common Shares
Olema Pharmaceuticals Files Initial Beneficial Ownership Statement for Sasha Lu, VP of Finance and Controller
Reuters  ·  02-18 10:33
Olema Pharmaceuticals Files Initial Beneficial Ownership Statement for Sasha Lu, VP of Finance and Controller
Chief Commercial Officer Pamela Stephenson Reports Disposal of Disc Medicine Inc. i Common Shares
Reuters  ·  02-18 10:16
Chief Commercial Officer Pamela Stephenson Reports Disposal of Disc Medicine Inc. i Common Shares
10% Owner Charles Cherington Reports Acquisition of Ernexa Therapeutics Inc. Common Shares
Reuters  ·  02-18 10:15
10% Owner Charles Cherington Reports Acquisition of Ernexa Therapeutics Inc. Common Shares
Disc Medicine CEO John D. Quisel Reports Sale of Common Shares
Reuters  ·  02-18 10:04
Disc Medicine CEO John D. Quisel Reports Sale of Common Shares
PTC Therapeutics Faces Translarna Setback While Valuation Signals Potential Upside
Simply Wall St.  ·  02-18 09:21
PTC Therapeutics Faces Translarna Setback While Valuation Signals Potential Upside
Nicole Murphy, Head of Pharm Ops and Tech, acquires Biogen Inc. common shares
Reuters  ·  02-18 09:17
Nicole Murphy, Head of Pharm Ops and Tech, acquires Biogen Inc. common shares
Director Srinivas Akkaraju Reports Acquisition of Kalaris Therapeutics Common Shares
Reuters  ·  02-18 09:16
Director Srinivas Akkaraju Reports Acquisition of Kalaris Therapeutics Common Shares
Alnylam CFO Jeffrey V. Poulton Reports Sale of Common Shares
Reuters  ·  02-18 08:26
Alnylam CFO Jeffrey V. Poulton Reports Sale of Common Shares
Halozyme Therapeutics Outlook FY Revenue USD 1,385-1,400 Million
Reuters  ·  02-18 08:01
Halozyme Therapeutics Outlook FY Revenue USD 1,385-1,400 Million
Mineralys Therapeutics Chief Medical Officer David Malcom Rodman Reports Common Share Disposal
Reuters  ·  02-18 07:57
Mineralys Therapeutics Chief Medical Officer David Malcom Rodman Reports Common Share Disposal
Synopsys Jumps over 2% While APLD Plunges 9%. Nvidia Reports Share Stake In Intel, Nokia, Synopsys; Dissolves In ARM, APLD
Reuters  ·  02-18 07:38
Synopsys Jumps over 2% While APLD Plunges 9%. Nvidia Reports Share Stake In Intel, Nokia, Synopsys; Dissolves In ARM, APLD

Introduction

Company Name.
BK4139
Affiliated Markets:
Listing Date:
--
Main Business:
Issue price:
--